A Retrospective Study of the C-Reactive Protein to Lymphocyte Ratio and Disease Severity in 108 Patients with Early COVID-19 Pneumonia from January to March 2020 in Wuhan, China

11 September 2020: Clinical Research

Miao Yang ^1ACDEG , Xiaoping Chen ^2ABCF* , Yancheng Xu ^1ADFG*

DOI: 10.12659/MSM.926393

Med Sci Monit 2020; 26:e926393

Table 1 Demographics, baseline characteristics, treatment and clinical outcomes of 108 COVID-19 patients.

	Total (n=108)	Non-severe (n=84)	Severe (n=24)	P-value
				0.034
Female	66 (61.1%)	56 (66.7%)	10 (41.7%)
Male	42 (38.9%)	28 (33.3%)	14 (58.3%)
	51.0 (35.0, 66.0)	46.0 (33.0, 62.0)	67.0 (55.0, 74.0)
	37 (34.3%)	20 (23.8%)	17 (70.8%)
Hypertension	16 (14.8%)	6 (7.1%)	10 (41.7%)	0.0002
Cardiovascular disease	6 (5.6%)	2 (2.4%)	4 (16.7%)	0.021
Diabetes	10 (9.3%)	7 (8.3%)	3 (12.5%)	0.689
Malignancy	3 (2.8%)	2 (2.4%)	1 (4.2%)	0.533
COPD	5 (4.6%)	1 (1.2%)	4 (16.7%)	0.008
Chronic liver disease	10 (9.3%)	5 (6.0%)	5 (20.8%)	0.042

Fever	71 (65.7%)	52 (61.9%)	19 (79.2%)	0.146
Fatigue	63 (58.3%)	45 (53.6%)	18 (75.0%)	0.066
Cough	56 (51.9%)	41 (48.8%)	15 (62.5%)	0.257
Myalgia	37 (34.3%)	27 (32.1%)	10 (41.7%)	0.466
Dyspnea	21 (19.4%)	10 (11.9%)	11 (45.8%)	0.0007
Diarrhea	17 (15.7%)	12 (14.3%)	5 (20.8%)	0.525
Headache	18 (16.7%)	12 (14.3%)	6 (25.0%)	0.225
	7.0 (4.0,10.0)	6.0 (3.0, 9.0)	8.0 (5.3, 10.0)	0.026

Oxygen support	63 (58.3%)	39 (46.4%)	24 (100.0%)
Antiviral therapy	73 (67.6%)	60 (71.4%)	13 (54.2%)	0.139
Antibiotic therapy	108 (100.0%)	84 (100.0%)	24 (100.0%)	–
Use of corticosteroid	53 (49.1%)	36 (42.9%)	17 (70.8%)	0.020
Use of immunoglobulin	29 (26.9%)	19 (22.6%)	10 (41.7%)	0.073
	14.0 (9.0, 20.0)	13.0 (8.0, 18.0)	20.5 (13.0, 28.5)	0.001
				0.0004
Discharged	103 (95.4%)	84 (100%)	19 (79.2%)
Death	5 (4.6%)	0 (0.0%)	5 (20.8%)
y – years; d – days; COPD – chronic obstructive pulmonary disease; IQR – interquartile range.